248 related articles for article (PubMed ID: 30025214)
1. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse and diversion.
Nalamachu SR; Shah B
Postgrad Med; 2022 May; 134(4):388-394. PubMed ID: 30025214
[TBL] [Abstract][Full Text] [Related]
2. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
3. Abuse-deterrent opioids: an update on current approaches and considerations.
Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
[TBL] [Abstract][Full Text] [Related]
4. Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States.
Iwanicki JL; Severtson SG; McDaniel H; Rosenblum A; Fong C; Cicero TJ; Ellis MS; Kurtz SP; Buttram ME; Dart RC
PLoS One; 2016; 11(12):e0167499. PubMed ID: 27936038
[TBL] [Abstract][Full Text] [Related]
5. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
Geoffrey Severtson S; Kreider SED; Amioka EC; Margolin ZR; Iwanicki JL; Dart RC
Pain Med; 2020 Dec; 21(12):3660-3668. PubMed ID: 33094329
[TBL] [Abstract][Full Text] [Related]
7. Opioids with abuse-deterrent properties: A regulatory and technological overview.
Haddox JD
J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
[TBL] [Abstract][Full Text] [Related]
8. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers.
Cicero TJ; Ellis MS; Kasper ZA
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):56-62. PubMed ID: 27594167
[TBL] [Abstract][Full Text] [Related]
9. The opioid crisis: a 21st century pain.
Walker G
Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
[TBL] [Abstract][Full Text] [Related]
10. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
Lee YH; Brown DL; Chen HY
Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
[TBL] [Abstract][Full Text] [Related]
11. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
[TBL] [Abstract][Full Text] [Related]
12. The US Opioid Crisis: Current Federal and State Legal Issues.
Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
[TBL] [Abstract][Full Text] [Related]
13. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
Rauck RL
Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
[TBL] [Abstract][Full Text] [Related]
14. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
Gasior M; Bond M; Malamut R
Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
[TBL] [Abstract][Full Text] [Related]
15. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.
Hale ME; Moe D; Bond M; Gasior M; Malamut R
Pain Manag; 2016 Oct; 6(5):497-508. PubMed ID: 27050830
[TBL] [Abstract][Full Text] [Related]
16. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
Webster LR; Markman J; Cone EJ; Niebler G
Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
[TBL] [Abstract][Full Text] [Related]
17. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access.
Webster L; Gudin J
J Pain Res; 2024; 17():1989-2000. PubMed ID: 38854928
[TBL] [Abstract][Full Text] [Related]
18. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
[TBL] [Abstract][Full Text] [Related]
19. Combating an Epidemic of Prescription Opioid Abuse.
Pon D; Awuah K; Curi D; Okyere E; Stern CS
J Calif Dent Assoc; 2015 Nov; 43(11):673-8. PubMed ID: 26798885
[TBL] [Abstract][Full Text] [Related]
20. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
